Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310269 · ClinicalTrials.gov registry record
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
A clinical trial, sponsored by Recordati Group.
- Completed
- Registry status
- 152
- Enrollment target
NCT02310269 is a clinical trial that has completed, run by Recordati Group. The registered enrollment target is 152 participants.
The verdict
NCT02310269 has completed, sponsored by Recordati Group.
- COMPLETED
- Registry status
- 152 participants
- Enrollment target
Study Summary
This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, each enrolled patient will be followed up for 3 years after enrollment. Patients who permanently discontinue pasireotide s.c. prior to completing the 3-year observation period will be followed up for 3 months after the last dose of pasireotide s.c.
Interventions
- DRUG Pasireotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2013-03-28 |
| Est. Completion | 2023-07-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02310269
The ClinicalTrials.gov registry entry for NCT02310269 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Recordati Group, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pasireotide is the first listed.
NCT02310269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02310269 about?
NCT02310269 is a clinical study titled "Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease". This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in...
What is the current status of trial NCT02310269?
This trial is currently completed. The enrollment target is 152 participants. The study started on 2013-03-28. Estimated completion is 2023-07-10.
What interventions are being tested in trial NCT02310269?
The interventions under investigation include: Pasireotide (DRUG).
Who is sponsoring clinical trial NCT02310269?
This trial is sponsored by Recordati Group, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.